IK930, a novel TEAD inhibitor, sensitizes KRAS and EGFR mutant tumors to oncogene targeted therapy
M. RajurkarIkena Oncology, Translational Research, Boston, USA;Manuel Sánchez‐MartínIkena Oncology, Translational Research, Boston, USA;D. HidalgoIkena Oncology, Translational Research, Boston, USA;N. YoungIkena Oncology, Molecular and Cellular Oncology, Boston, USA;B. AmidonIkena Oncology, Molecular and Cellular Oncology, Boston, USA;G. PunkosdyIkena Oncology, In vivo Pharmacology, Boston, USA;J. EcsedyIkena Oncology, Discovery Biology, Boston, USALiwen XuIkena Oncology, Translational Research, Boston, USA;
ABI
Abstract
No abstract available.
Topics
Identifiers
Citations and references
Cited by 00 references